• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Kent R Intelligibility in speech disorders


    [7] Kent R. Intelligibility in speech disorders. Amsterdam/Philadelphia: John Ben-jamins; 1992.
    [8] Yorkston KM, Beukelman DR, Tice TR. Sentence intelligibility test. Lincoln, NE: Tice technology services; 1996.
    [9] Auzou P. Les objectifs du bilan de la dysarthrie. In: Auzou P, Rolland Mon-
    [11] Middag C. Automatic analysis of pathological speech. Ghent, Belgium: Ghent University, Department of Electronics and information systems; 2012.
    [12] Astesano C, Balaguer M, Farinas J, Fredouille C, Gaillard P, Ghio A, et al. Carcino-logic speech severity index project: a database of speech disorders productions to assess quality of life related to speech after cancer. Miyazaki Japan: LREC; 2018.
    [14] Plisson L, Pillot-Loiseau C, Crevier-Buchman L. Intelligibilité de la parole après le traitement d’un cancer de l’oropharynx : étude descriptive chez sept patients en pré-traitement et en post-traitement précoce; 2017 [7e Journées de phonétique clinique (JPC7), Jun 2017, Paris, France].
    [16] Dittner J, Lepage B, Woisard V, Kergadallan M, Boisteaux K, Robert E, et al. Elaboration et validation d’un test quantitatif d’intelligibilité pour les trou-bles pathologiques de la production de parole. Rev Laryngol Otol Rhinol 2010;131(1):9–14.
    The authors declare that they Actinomycin D have no competing interest.
    Please cite this article in press as: Balaguer M, et al. Actinomycin D Assessment of impairment of intelligibility and of speech sig-nal after oral cavity and oropharynx cancer. European Annals of Otorhinolaryngology, Head and Neck diseases (2019),
    J Stomatol Oral Maxillofac Surg xxx (2018) xxx–xxx
    Available online at
    Original Article
    Assessment of salivary endothelin-1 in patients with leukoplakia, submucous fibrosis, oral cancer and healthy individuals – a comparative study
    a Faculty of Dental Sciences, Ramaiah University of Applied Sciences, India b M.S Ramaiah Medical College And Hospital, India
    Article history:
    Background: Oral cancer is one of the highly prevalent cancers worldwide being. According to data of GLOBOCAN 2018, the estimated incidence, mortality and 5-year survival rates due to lip, oral cavity and salivary gland cancer in world is (2.0%), (0.5%) and (0.3%) respectively. (Bray, Ferlay and Soerjomataram, 2018). Endothelin-1 (ET-1) is a 21-amino acid peptide; its receptors have been implicated in the growth and progression of both primary and metastatic neoplasms throughout the human body. Studies have shown that ET-1 is expressed in tissue, serum and other body fluids.
    Aim: To estimate the levels of salivary endothelin-1 in Oral potentially malignant disorders (oral leukoplakia and submucous fibrosis) and oral squamous cell carcinoma.
    Materials and methods: The study population included 60 subjects and were divided into 4 groups. All patients included in the study are clinically and histopathological diagnosed cases of oral leukoplakia, submucous fibrosis and oral cancer and assessed for salivary ET-1 levels using human ELISA kit. Significant differences between the groups were determined using one-way analysis of variance, LSD and Post HOC, unpaired t test, biserial and spearson’s correlation.
    Results: The mean levels of salivary Endothelin-1 level in study groups were: 82.78 5.9 pg/mL (OSCC), 65.02 1.8 pg/mL (SMF), 57.76 4.1 pg/mL (LEUKOPLAKIA), 29.72 14.1 pg/mL (CONTROLS). The mean Salivary ET-1 levels among these four groups was compared and the difference was statistically significant (P < 0.001). We also found a significant difference in the means of ET-1 levels among the clinical and histopathological staging of the study groups.
    Conclusion: Our results demonstrate potential utility of salivary analysis for ET-1 levels to monitor patients at risk for OSCC. Although provides the basis for a larger prospective study to determine the critical levels of salivary ET-1 necessary to diagnose and monitor OPMD’s and its potential to undergo malignant transformation.
    C 2019 Elsevier Masson SAS. All rights reserved.
    1. Introduction
    Oral cancer is one of the highly prevalent cancers worldwide being a leading cause of mortality. According to data of GLOBOCAN 2018, the estimated incidence, mortality and 5-year survival rates due to lip, oral cavity and salivary gland cancer in the world is (2.0%), (0.5%) and (0.3%) respectively [1]. Oral cancer is being reported as the third most common type, representing over 30% of all cancers in the nation. Age-balanced rates of oral cancer stated by different oral cancer registries in India change from 8 to 20 for
    * Corresponding author.